Phaseline

Targets › OPRK1

OPRK1 (Kappa-type opioid receptor): drug programs, companies and trials

24 programs from 23 companies in 105 trials: 38 Phase 4, 35 Phase 2, 16 Phase 3, 16 Phase 1; Psychiatry, Other, Neurology; next expected readout Nov 2026.

G protein-coupled opioid receptor that functions as a receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as a receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of…. (UniProt, P41145)

Open in Phaseline: the race on OPRK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Pennsylvania2-[18F]-FA
Voltage-gated calcium channel modulator
CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STNPhase 4Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis …Nov 2026
Peking University First HospitalAnrikefon
Selective peripheral κ-opioid receptor agonist
OPRK1Phase 4Laparoscopic SurgeryMar 2027
New York State Psychiatric InstituteOlanzapine-samidorphan
Atypical antipsychotic (D2 dopamine receptor antagonist) combined with opioid antagonist (
DRD2, OPRK1Phase 4Schizophenia DisorderApr 2027
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityAnrikefon
peripherally-restricted KOR agonist
OPRK1Phase 4Ophthalmic SurgeryDec 2027
Currax PharmaceuticalsNaltrexone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4ObesityJan 2029
Middle Tennessee Research InstituteNaloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4Low Back Pain–
University of Colorado, DenverNaloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4Harm Reduction–
Friends Research Institute, Inc.Naloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4Opioid Use Disorder–
Pouya AzarNaloxone Hydrochloride
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4Opioid Use Disorder–
University of Maryland, BaltimoreNaloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 3Opioid Use Disorder; PainNov 2026
Adneuris TherapeuticsCebranopadol
Nociceptin receptor agonist; Opioid receptors; mu/kappa/delta agonist
OPRL1, OPRK1, OPRD1, OPRM1Phase 3Pain; Chronic PainJan 2027
Trevi TherapeuticsNalbuphine
Opioid receptors; mu/kappa/delta agonist
OPRK1, OPRD1, OPRM1Phase 3Idiopathic Pulmonary Fibrosis; Refractory Chronic Cough; Laryngoscopy; Postoperative Pain, Acute …Aug 2027
AgelessRxNaltrexone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 3Healthspan Improvement; Longevity; Human Immunodeficiency Virus; Obesity; Drug …–
AlkermesSamidorphan
Mu opioid receptor antagonist; Kappa opioid receptor partial agonist; Delta opioid receptor partial agonist
OPRM1, OPRK1, OPRD1Phase 3Schizophrenia–
Tianjin Medical University Cancer Institute and HospitalAnruikefen
Peripherally selective kappa receptor agonist
OPRK1Phase 2GastrectomyDec 2026
Medical University of LublinNaltrexone Hydrochloride
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 2VulvodyniaDec 2026
New York State Psychiatric InstituteNaloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 2Opioid-use DisorderJan 2027
Tioga PharmaceuticalsAsimadoline (TP0052)
Kappa opioid receptor agonist
OPRK1Phase 2Vasomotor SymptomsOct 2027
University of British ColumbiaNaloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 2Opioid-use DisorderDec 2027
Vifor Fresenius Medical Care Renal PharmaDifelikefalin
Kappa opioid receptor agonist
OPRK1Phase 2PruritusAug 2029
ReacX PharmaceuticalsNalmefene
Mu opioid receptor antagonist; Delta opioid receptor antagonist; Kappa opioid receptor partial agonist
OPRM1, OPRD1, OPRK1Phase 1Opioid Abuse and Addiction; Behavioural AddictionDec 2026
Johnson & Johnson (Janssen)Aticaprant (JNJ-67953964)
Kappa opioid receptor antagonist
OPRK1Phase 1SchizophreniaJun 2027
Boulder CareBuprenorphine
Mu opioid receptor agonist; Kappa opioid receptor agonist
OPRM1, OPRK1Phase 1Opioid Use Disorder; Postoperative Pain; Pain, Postoperative; Acute Postoperative Pain …Aug 2027
Akyso TherapeuticsNaltrexone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 1Opioid Use DisorderOct 2029

Conditions

Opioid Use Disorder (23) Opioid-use Disorder (5) Alcohol Use Disorder (5) Opioid Use Disorder (OUD) (3) Analgesia (3) Schizophrenia (3) Idiopathic Pulmonary Fibrosis (2) Pain (2) Pain, Postoperative (2) Chronic Pain (2) Head and Neck Squamous Cell Carcinoma (2) Gastrectomy (1)

Modalities

small molecule (21), mixed (2)

Companies

New York State Psychiatric Institute (2) Tianjin Medical University Cancer Institute and Hospital (1) Middle Tennessee Research Institute (1) Trevi Therapeutics (1) Currax Pharmaceuticals (1) University of British Columbia (1) AgelessRx (1) ReacX Pharmaceuticals (1) Akyso Therapeutics (1) University of Maryland, Baltimore (1) Boulder Care (1) Pouya Azar (1) Peking University First Hospital (1) University of Colorado, Denver (1) Friends Research Institute, Inc. (1) Zhongshan Ophthalmic Center, Sun Yat-sen University (1) Adneuris Therapeutics (1) Medical University of Lublin (1) University of Pennsylvania (1) Johnson & Johnson (Janssen) (1)

Related targets

OPRM1 (17) OPRD1 (16) DRD2 (1) OPRL1 (1) CHRNA4 (1) UL51 (1) ADRA2A (1) ADRA2C (1) ADRA2B (1) Ion channels (1) CACNB4 (1) CACNB2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.